Top 10 Russell 2000 Weekly Gainers and Losers as Wall Street Crashes
When Should You Buy RxSight, Inc. (NASDAQ:RXST)?
SA Rating Changes: CHTR, RIVN, EE, WASH, DV, LZ, RXST
JP Morgan Downgrades RxSight on Market, Competitive Pressures
A Quick Look at Today's Ratings for RxSight(RXST.US), With a Forecast Between $22 to $43
Deep Dive Into RxSight Stock: Analyst Perspectives (12 Ratings)
JP Morgan Downgrades RxSight to Underweight, Lowers Price Target to $17
RxSight Inc (RXST) Q1 2025 Earnings Call Highlights: Strong Year-Over-Year Growth Amid Revised ...
Aptevo Therapeutics APVO +44% Private Placement; RxSight RXST -38% Earnings
Rxsight Adjusts 2025 Revenue Guidance to $160M-$175M Amid Premium IOL Market Challenges
Top Midday Decliners
RxSight Down Over 38%, On Track for Record Percent Decrease -- Data Talk
RxSight Stock Tumbles on Lowered 2025 Guidance
RxSight RXST Preliminary Revenue; Aldeyra ALDX CRL
RxSight Q1 Revenue Miss, Guidance Cut Raise Growth Concerns, BofA Says
RxSight Is Maintained at Equal-Weight by Wells Fargo
Dow Tumbles Over 1,100 Points; US Initial Jobless Claims Fall
Sector Update: Health Care Stocks Lean Lower Premarket Thursday
Sector Update: Health Care
RxSight Shares Are Trading Lower After the Company Issued FY25 Revenue Guidance Below Estimates.